HNSA Share Price Performance
SEK 0
-29.88 (-100.00%)
Price SEK 0
Fair ValueSEK 143.00
Share Pricen/a
Hansa Biopharma AB (publ) (STO:HNSA) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Nov 16
Hansa Biopharma AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
HNSA Community Narratives
AN
Fair Value SEK 143 80.4% undervalued intrinsic discount
Accelerated Immunotherapy Adoption Will Fuel Global Market Expansion
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value SEK 90 68.9% undervalued intrinsic discount
Global Organ Transplantation Demand Will Expand Market Opportunity
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value SEK 37 24.4% undervalued intrinsic discount
European Organ Allocation Will Face Volatility Yet Allow Recovery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Accelerated Immunotherapy Adoption Will Fuel Global Market Expansion
Key Takeaways Accelerating market adoption, strategic partnerships, and regulatory momentum are positioning IDEFIRIX and imlifidase for stronger revenue and profit growth than currently expected. Cost-cutting measures and executive restructuring enhance operational savings, supporting margin expansion regardless of sales fluctuations, while novel therapies open up new, underappreciated revenue streams.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
SEK 143
80.4% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
126.61% p.a.
Profit Margin
42.03%
Future PE
17.93x
Share price in 2028
SEK 104.07
Global Organ Transplantation Demand Will Expand Market Opportunity
Key Takeaways Expansion into new markets, improved reimbursement, and strong transplant demand are driving significant sales and margin growth for IDEFIRIX and other biologics. Advancing pipeline diversification and upcoming clinical readouts reduce single-product dependency, positioning for multi-asset growth and enhanced long-term earnings potential.Read more
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
SEK 90
68.9% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
89.78% p.a.
Profit Margin
27.96%
Future PE
28.8x
Share price in 2028
SEK 65.33
European Organ Allocation Will Face Volatility Yet Allow Recovery
Key Takeaways Heavy reliance on successful pipeline expansion and regulatory approvals creates vulnerability to setbacks, potentially destabilizing revenue prospects and overall business sustainability. Policy shifts, pricing pressures, and competition from larger pharma and biosimilars could compress margins and restrict long-term earnings growth.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 37
24.4% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
66.47% p.a.
Profit Margin
20.44%
Future PE
23.99x
Share price in 2028
SEK 26.85
Recently Updated Narratives
AN
Global Organ Transplantation Demand Will Expand Market Opportunity
Fair Value: SEK 90 68.9% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
European Organ Allocation Will Face Volatility Yet Allow Recovery
Fair Value: SEK 37 24.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Accelerated Immunotherapy Adoption Will Fuel Global Market Expansion
Fair Value: SEK 143 80.4% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Hansa Biopharma AB (publ) Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 05, 2026
- -6.30
- 59.47%
- -358.96%
- -163.1%
About HNSA
- Founded
- 2007
- Employees
- 133
- CEO
- WebsiteView website
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
